Induction of tumour necrosis factor and interferon-γ in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites

Biochemical Pharmacology

Volumn 67, Issue 5, 2004, Pages 937-945

  Wang, Liang Chuan S ^a   Reddy, Charu B ^a   Baguley, Bruce C ^a   Kestell, Philip ^a   Sutherland, Rachel ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Glucuronide; Lipopolysaccharide; Okadaic acid; Phorbol myristate acetate; Splenocytes

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID GLUCURONIDE; 6 HYDROXY 5 METHYLXANTHENONE ACETIC ACID; CARBOHYDRATE DERIVATIVE; DRUG METABOLITE; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL CELL; ARTICLE; BLEEDING; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; IN VITRO STUDY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SPLEEN CELL; STIMULATION; TIME; TUMOR; TUMOR NECROSIS;

EID: 1042263997     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.10.023     Document Type: Article

References (30)

1. Baguley B.C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4:2003;141-148.
2. Philpott M., Baguley B.C., Ching L-M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 36:1995;143-148.
3. Perera P.Y., Barber S.A., Ching L.M., Vogel S.N. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages - dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J. Immunol. 153:1994;4684-4693.
4. Cao Z., Baguley B.C., Ching L-M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61:2001;1517-1521.
5. Browne W.L., Wilson W.R., Baguley B.C., Ching L-M. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res. 18:1998;4409-4414.
6. Baguley B.C., Ching L-M. DMXAA: an antivascular agent with multiple host responses. Int. J. Radiat. Oncol. Biol. Phys. 54:2002;1503-1511.
7. Zhao L., Ching L.M., Kestell P., Baguley B.C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer. 87:2002;465-470.
8. Futami H., Eader L.A., Back T.T., Gruys E., Young H.A., Wiltrout R.H., Baguley B.C. Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. J. Immunother. 12:1992;247-255.
9. Pang J-H., Cao Z., Joseph W.R., Baguley B.C., Ching L-M. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur. J. Cancer. 34:1998;1282-1289.
10. Dvorak H.F., Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 81:1989;497-502.
11. Sgadari C., Angiolillo A.L., Cherney B.W., Pike S.E., Farber J.M., Koniaris L.G., Vanguri P., Burd P.R., Sheikh N., Gupta G., Teruyafeldstein J., Tosato G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. U.S.A. 93:1996;13791-13796.
12. Joseph W.R., Cao Z., Mountjoy K.G., Marshall E.S., Baguley B.C., Ching L-M. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 59:1999;633-638.
13. Ching L.M., Goldsmith D., Joseph W.R., Korner H., Sedgwick J.D., Baguley B.C. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59:1999;3304-3307.
14. Philpott M., Ching L.M., Baguley B.C. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator to other inducers of tumour necrosis factor. Eur. J. Cancer. 37:2001;1930-1937.
15. Jameson M.B., Thompson P.I., Baguley B.C., Evans B.D., Harvey V.J., Porter D.J., McCrystal M.R., Kestell P. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Am. Soc. Clin. Oncol. 19:2000;182a.
16. McKeage M.J., Kestell P., Denny W.A., Baguley B.C. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother. Pharmacol. 28:1991;409-413.
17. Kestell P., Paxton J.W., Rewcastle G.W., Dunlop I., Baguley B.C. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethyl-xanthenone-4-acetic acid in mouse, rat and rabbit. Cancer Chemother. Pharmacol. 43:1999;323-330.
18. Chabot G.G., Bissery M-C., Gouyette A. Flavone acetic acid (LM-975; NSC-347512) activation to a cytotoxic species in vivo and in vitro. Cancer Chemother. Pharmacol. 24:1989;273-276.
19. Rewcastle G.W., Atwell G.J., Zhuang L., Baguley B.C., Denny W.A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 34:1991;217-222.
20. Zhou S., Paxton J.W., Tingle M.D., McCall J., Kestell P. Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone- 4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 734:1999;129-136.
21. Jameson M.B., Thompson P.I., Baguley B.C., Evans B.D., Harvey V.J., Porter D.J., McCrystal M.R., Small M., Bellenger K., Gumbrell L., Halbert G.W., Kestell P. Phase I trial of the antivascular agent 5,6-dimethylxanthenone-4- acetic acid (DMXAA). Br. J. Cancer. 88:2003;1844-1850.
22. Baguley B.C., Cole G., Thomsen L.L., Zhuang L. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 33:1993;77-81.
23. Peters P.M., Ortaldo J.R., Shalaby M.R., Svedersky L.P., Nedwin G.E., Bringman T.S., Hass P.E., Aggarwal B.B., Herberman R.B., Goeddel D.V. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J. Immunol. 137:1986;2592-2598.
24. Fultz M.J., Barber S.A., Dieffenbach C.W., Vogel S.N. Induction of IFN-gamma in macrophages by lipopolysaccharide. Int. Immunol. 5:1993;1383-1392.
25. Gerweck L.E., Rhee J.G., Koutcher J.A., Song C.W., Urano M. Regulation of pH in murine tumor and muscle. Radiat. Res. 126:1991;206-209.
26. Woon S-T., Baguley B.C., Palmer B.D., Fraser J.D., Ching L-M. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappa B in human tumor cell lines. Oncol. Res. 13:2002;95-101.
27. Ludwig M-G., Vanek M., Guerini D., Gasser J.A., Jones C.E., Junker U., Hofstetter H., Wolf R.M., Seuwen K. Proton-sensing G-protein-coupled receptors. Nature. 425:2003;93-98.
28. Xu L., Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol. Res. 12:2000;97-106.
29. Bellocq A., Suberville S., Philippe C., Bertrand F., Perez J., Fouqueray B., Cherqui G., Baud L. Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-kappa B activation. J. Biol. Chem. 273:1998;5086-5092.
30. Sayers T.J., Wiltrout T.A., McCormick K., Husted C., Wiltrout R.H. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res. 50:1990;5414-5420.